VirTrial has announced an alliance with Pratia, the network of clinical research centers in Europe. All Pratia research centers have completed VirTrial’s Virtual Trial Capable training, making them trained and certified as Virtual Trial Capable and prepared to conduct decentralized clinical trials (DCT).
The training program includes four modules that clinical research professionals complete to demonstrate a level of competence in general telemedicine etiquette and guidelines, as well as how to utilize the VirTrial platform. Participants then receive a Virtual Trial Capable certificate and badge to highlight to sponsors and CROs that they are prepared to conduct hybrid decentralized clinical trials.
“Pratia’s mission is to facilitate access to healthcare to improve the quality of life and the sense of security of our patients. Embracing telehealth technologies that enable a larger patient population to participate supports our goal and we’re proud to be the first network in Europe to offer this benefit to sponsors,” said MaÅgorzata Gerjatowicz-OsmaÅska, Managing Director of Pratia. “Our network is expanding across Europe and we plan to maintain our 100% Virtual Trial Capable status with VirTrial to best serve our patients and pharma sponsors.”
Amanda Rangel, VP of Business Development for VirTrial, remarked, “VirTrial is honored to collaborate with forward-thinking sites like those in the Pratia network that are taking action to move the industry forward and improve patient access to clinical trials. The innovative VirTrial telehealth platform was developed by clinical research professionals and we are committed to continued collaboration with sites and supporting site sustainability in the new era of hybrid decentralized trials.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.